Platelet antithrombin defect in malignancy: platelet protein alterations

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Platelet function is crucial in hemostasis and can be altered in patients with malignant diseases.
• The platelet antithrombin test (PAT) can identify abnormalities in platelet function related to coagulation.
• Specific platelet glycoproteins play vital roles in platelet adhesion and aggregation.

Purpose of the Study:

• To investigate alterations in platelet polypeptide and glycoprotein composition in patients with malignant disease and abnormal PAT results.
• To identify specific platelet proteins affected in a subpopulation of cancer patients with decreased antithrombin activity.

Main Methods:

• Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis was used to analyze platelet polypeptide composition.
• Tritium labeling and two-dimensional electrophoresis were employed to study platelet surface glycoproteins.
• Immunoblotting with anti-human platelet glycocalicin antiserum and ristocetin-induced platelet agglutination assays were performed.

Main Results:

• A polypeptide of 180,000 apparent mol wt, identified as thrombospondin, was decreased or absent in platelets from patients with abnormal PAT.
• A glycoprotein of 140,000 apparent mol wt (GPIb) was decreased in all patients with abnormal PAT.
• Patients with abnormal PAT exhibited significantly reduced ristocetin-induced platelet agglutination compared to those with normal PAT.

Conclusions:

• Platelets from a subpopulation of tumor patients with decreased antithrombin activity show alterations in GPIb and thrombospondin.
• These glycoprotein changes may contribute to the observed hemostatic abnormalities in cancer patients.
• The study identifies specific molecular defects in platelets associated with malignant disease.